Kiniksa Pharmaceuticals International (KNSA) EV to EBIT (2018 - 2026)
Kiniksa Pharmaceuticals International's (KNSA) quarterly EV to EBIT came in at 347.52 in Q2 2026, up 90.61% on a YoY basis from 182.32 in Q2 2025, and up 46.79% quarter-over-quarter from 236.75 in Q1 2026.
Powered by 
Analysis
Kiniksa Pharmaceuticals International (KNSA) EV to EBIT (2018 - 2026) Analysis & Trends
Kiniksa Pharmaceuticals International (KNSA) has reported EV to EBIT for 9 consecutive years, with 347.52 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, EV to EBIT rose 90.61% year-over-year to 347.52; the trailing twelve-month figure through Jun 2026 stood at 94.27 (down 88.52% YoY), and the FY2025 full-year result was 76.28, up 232.29% from the prior year.
- EV to EBIT climbed to 347.52 in Q2 2026 per KNSA's latest filing, from 236.75 in the prior quarter.
- Across five years, EV to EBIT topped out at 28001.18 in Q4 2023 and bottomed at 19820.35 in Q2 2024.
- Historically, EV to EBIT has averaged 468.7 across 5 years, with a median of 9.33 in 2022.
- The sharpest annual moves came in 2023 and 2024: EV to EBIT soared 8819.43% in 2023, then plunged 3537.68% in 2024.
- Over 5 years, EV to EBIT stood at 313.93 in 2022, then jumped by 8819.43% to 28001.18 in 2023, then slumped by 100.49% to 136.29 in 2024, then surged by 318.63% to 297.96 in 2025, then rose by 16.63% to 347.52 in 2026.
- According to Business Quant data, EV to EBIT over the past three periods registered 347.52, 236.75, and 297.96 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn |
| 10 | Kiniksa Pharmaceuticals International | 6.09 Bn | 5.56 Bn | 220.03 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 347.52 |
| Mar 31, 2026 | 236.75 |
| Dec 31, 2025 | 297.96 |
| Sep 30, 2025 | 223.01 |
| Jun 30, 2025 | 182.32 |
| Mar 31, 2025 | 215.34 |
| Dec 31, 2024 | -136.29 |
| Sep 30, 2024 | -337.27 |
| Jun 30, 2024 | -19,820.35 |
| Mar 31, 2024 | -146.54 |
| Dec 31, 2023 | 28,001.18 |
| Sep 30, 2023 | -197.60 |
| Jun 30, 2023 | -544.86 |
| Mar 31, 2023 | -117.54 |
| Dec 31, 2022 | 313.93 |
| Sep 30, 2022 | 34.14 |
| Jun 30, 2022 | -62.36 |
| Mar 31, 2022 | -52.81 |
| Dec 31, 2021 | -39.97 |
| Sep 30, 2021 | -44.32 |